Question 1

What are the potential side effects of Endostar and Toripalimab?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma clinical trial (NCT05907512). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to other options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma clinical trial (NCT05907512). Contact the study team or your healthcare provider for specific answers.

Question 3

What is the expected duration of treatment and how often will I need to come in for visits?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma clinical trial (NCT05907512). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any specific tests or evaluations I will need to undergo during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma clinical trial (NCT05907512). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects or my condition worsens during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma clinical trial (NCT05907512). Contact the study team or your healthcare provider for specific answers.

What this study is about